U.S. stock futures rise as investors brace for a high-stakes week packed with Tesla and Alphabet earnings and growing anxiety ...

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

Analysts are intrested in these 5 stocks: ( ($JPM) ), ( ($SBUX) ), ( ($HPE) ), ( ($SRPT) ) and ( ($ELV) ). Here is a breakdown of their recent ...

Sarepta's gene therapy pipeline faces renewed scrutiny after a third patient death and FDA plans for a black box warning on ...

Key Takeaways Sarepta Therapeutics shares were down roughly 17% late Friday morning.The tumble followed a report that a third ...

The cross-asset moves come at the end of a week marked by market jitters over speculation that President Donald Trump might ...

Scott Rubner, Citadel Securities' new head of equity and equity derivatives strategy, expects "robust" retail trading flows ...

He's a regular tracker of volatility control funds - "vol control" - or strategies used increasingly by big institutions such as pensions and longer-term endowment funds to keep risk on an even keel.

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...